What is Livagen ?
Livagen is a synthetic tetrapeptide with the verified sequence Lys-Glu-Asp-Ala (KEDA), developed by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology as a synthetic analog of the natural liver polypeptide complex Ventvil. The compound is documented in approximately 15 PubMed-indexed papers across two collaborating research networks (Khavinson institute in St. Petersburg; Lezhava and Dzhokhadze group in Tbilisi). The most-cited mechanism (PMID 12533768, Bull Exp Biol Med 2002) is epigenetic chromatin remodeling: ex vivo treatment of lymphocytes from elderly donors induced decondensation of pericentromeric structural heterochromatin and reactivated age-silenced ribosomal RNA genes. Additional documented activities include enkephalinase inhibition in human serum (IC50 ~20 micromolar, PMID 12942748), age-normalization of digestive enzyme activity in rats given oral KEDA (PMID 16075683), and hepatocyte protein synthesis enhancement in cultured rat liver cells (PMID 15926314). A 2020 Khavinson-group review (PMID 32362099) synthesizes animal hepatitis and cirrhosis model data. No randomized controlled trial, no human pharmacokinetic study, and no fully independent (non-Khavinson-network) Western replication has been published. IMPORTANT SEQUENCE CORRECTION: Livagen is KEDA, not KEDG. KEDG is the sequence for Testagen, a different Khavinson peptide. Vendors and biohacking sources occasionally cite the wrong sequence.
















